



November 22, 2021

Office of the Vermont Attorney General  
109 State Street  
Montpelier, VT 05609  
Re: New High-Cost Prescription Drugs Reporting

Dear Office of the Vermont Attorney General,

In compliance with 18 V.S.A. § 4637, Amneal Pharmaceuticals LLC (“Amneal”) has introduced new generic prescription drugs (“Products”) at a wholesale acquisition cost that is over the threshold set for a specialty drug under the Medicare Part D program, which is attached as Exhibit A. This letter also provides the additional required information by 18 V.S.A. § 4637(c) regarding the Product. Amneal notes that the Office of the Attorney General has not yet prescribed a format for submissions under this section. Further, as authorized by 18 V.S.A. § 4637(d), Amneal has limited the information reported to that which is in the public domain or publicly available.

1. A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;
  - › *This drug is a generic product; therefore no marketing and pricing plans are available.*
  - This Product is sold in the United States only.*
2. The estimated volume of patients who may be prescribed the drug;
  - › *The estimated average number of patients per month is unknown to Amneal.*
3. Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval;
  - › *Not applicable.*
4. The date and price of acquisition if the drug was not developed by the manufacturer;
  - › *Amneal did not acquire this product.*

Sincerely,

A handwritten signature in blue ink that reads "William E. Riker".

William E. Riker  
Senior Director, Pricing & Contracts

Exhibit A

<b>NDC</b>	<b>PRODUCT</b>	<b>DATE OF INTRO TO MARKET</b>	<b>WAC</b>
60219203601	Azathioprine Tablet 75mg 100	11/22/2021	\$1408.49